Luise Weigand
Chief Scientific Officer Zelluna Immunotherapy
Luise Weigand joined Zelluna Immunotherapy in January 2021 and serves as Chief Scientific Officer. Prior to joining Zelluna, Luise was Associate Director Translational Medicine at Autolus, setting up and delivering clinical biomarker analysis for a couple of clinical trials, as well as leading projects in early-stage clinical trials at cross functional level. Luise previously spent over 7 years at Immunocore Ltd, where she built and led scientific teams from TCR discovery, through preclinical to early development. Luise received her PhD from the Technical University of Munich/Helmholtz Zentrum Muenchen in cancer immunotherapy in 2011.
Seminars
Tuesday 19th May 2026
C-Level Fireside Chat: Reflecting on Lessons from TCR Therapies to Drive Next-Generation Strategies
9:00 am
- Identifying pivotal learnings that can sharpen development strategies and accelerate stronger clinical outcomes
- Framing actionable insights that translate early proof-of-concept gains into durable, real-world clinical impact
- Exploring critical knowledge gaps and defining high-value priorities that can shape the next-generation of TCR innovations
